Clinical Trial Update: Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a triplet combination of glofitamab, polatuzumab vedotin, and zanubrutinib as first-line therapy in elderly patients with Diffuse Large…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Brukinsa (zanubrutinib) (zanubrutinib)
• Columvi (glofitamab) (glofitamab)
• Polivy (polatuzumab vedotin) (polatuzumab vedotin)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING